Mario Airoldi

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up

Sara Bustreo, Simona Osella‐Abate, Paola Cassoni et al. · Breast Cancer Research and Treatment · 2016 · 214 citations · Full text

Breast Oncology, Prognosis, Estrogen Receptor +16

Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies

Mario Airoldi, Fulvia Pedani, Giovanni Succo et al. · Cancer · 2001 · 180 citations · Full text

Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer

Claudio Zanon, Renzo Clara, Isabella Chiappino et al. · World Journal of Surgery · 2004 · 113 citations

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, <i>ERBB2</i>-Negative Advanced Breast Cancer

Antonio Llombart‐Cussac, José Manuel Pérez-García, Meritxell Bellet et al. · JAMA Oncology · 2021 · 99 citations · Full text